TLPH TALPHERA, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1427925 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-96.3%
TTM net income YoY-33.4%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,474,700.0%
Net margin-1,507,600.0%
FCF margin—
EBITDA margin—
Returns
ROE-143.4%
ROA-69.6%
ROIC (approx.)-172.6%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets46.3%
Debt / equity0.00x
Current ratio4.29x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-13.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $28,000 | $0 | $651,000 | $0 | $2.82M |
| Cost of revenue | — | — | — | $2.59M | $3.75M |
| Gross profit | — | — | — | -$2.59M | -$935,000 |
| R&D expense | $6.03M | $6.72M | $5.55M | $3.34M | $4.09M |
| SG&A expense | $7.48M | $8.53M | $11.99M | $17.01M | $30.93M |
| Operating income | -$13.48M | -$15.25M | -$16.89M | -$25.30M | -$35.97M |
| Interest expense | — | $0 | $134,000 | $1.12M | $2.29M |
| Pretax income | — | — | -$10.29M | $59.14M | -$35.09M |
| Income tax | $0 | $0 | $0 | $13,000 | $5,000 |
| Net income | -$14.29M | -$13.00M | -$18.40M | $47.76M | -$35.10M |
| EBITDA | — | -$15.25M | -$16.58M | -$23.65M | -$33.99M |
| EPS (basic) | -0.34 | -0.50 | -1.29 | 5.73 | -5.86 |
| EPS (diluted) | — | — | -1.29 | 5.72 | -5.86 |
| Weighted avg. shares (diluted) | — | — | 14.26M | 7.41M | 5.99M |
| Balance sheet | |||||
| Cash & equivalents | $5.89M | $8.86M | $5.72M | $15.28M | $7.66M |
| Short-term investments | $14.49M | $0 | $3.66M | $495,000 | $38.97M |
| Receivables | — | — | — | $309,000 | $160,000 |
| Inventory | — | — | — | $1.18M | $1.11M |
| Current assets | $20.90M | $9.42M | $11.58M | $24.57M | $50.49M |
| PP&E, net | — | — | — | $10.26M | $15.93M |
| Intangibles | $8.82M | $8.82M | $8.82M | $8.82M | $0 |
| Total assets | $29.72M | $18.24M | $20.39M | $47.49M | $77.89M |
| Current liabilities | $3.81M | $2.65M | $4.51M | $13.77M | $18.51M |
| Short-term debt | — | — | $0 | $5.36M | $8.80M |
| Long-term debt | — | — | — | $0 | $5.01M |
| Total debt | — | — | — | $5.36M | $13.80M |
| Total liabilities | $12.68M | $10.23M | $6.29M | $25.67M | $113.79M |
| Shareholders' equity | $17.04M | $8.00M | $14.11M | $21.81M | -$35.89M |
| Net debt | — | — | — | -$9.91M | $6.14M |
| Shares outstanding | 49.33M | 17.03M | 16.95M | 8.24M | 6.84M |
| Cash flow statement | |||||
| Operating cash flow | -$11.36M | -$12.68M | -$17.49M | -$28.33M | -$30.00M |
| Capital expenditure | — | $0 | $100,000 | $364,000 | $1.83M |
| Free cash flow | — | -$12.68M | -$17.59M | -$28.70M | -$31.83M |
| Investing cash flow | -$14.35M | $3.78M | -$528,000 | $36.45M | -$26.12M |
| Financing cash flow | $22.74M | $12.04M | $3.47M | -$507,000 | $41.51M |
| Depreciation & amortization | — | $0 | $311,000 | $1.65M | $1.97M |
| Stock-based compensation | $699,000 | $989,000 | $1.73M | $2.89M | $4.61M |
Free plan shows the latest 5 periods; Pro shows all 20 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.